Johnson & Johnson (JNJ)

The U.S. Food and Drug Administration has approved Johnson & Johnson's drug delivery system for patients with a type of bladder cancer, the drugmaker said on Tuesday, offering a potential alternative ...

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?

Johnson & Johnson stock (NYSE: JNJ) has delivered a remarkable 24% return in 2025 even as the S&P 500 healthcare index declined 0.2%. This raises an important question: Is this outperformance grounded...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been...

ABBV and JNJ face patent cliffs but show resilience with strong pipelines, acquisitions and promising growth drivers.

I reiterate my buy rating on JNJ, supported by steady EPS growth, robust free cash flow, and an attractive valuation. Recent quarterly results beat expectations, with management raising guidance and a...

Explore the exciting world of Johnson & Johnson (JNJ -0.31%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into mark...

Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price and are well-covered. Analyst forecasts suggest top Dow Dogs could de...

The list of trillion-dollar stocks is small and doesn't feature a single medical company. That might change in the next decade, as several leading healthcare stocks have market caps that are inching c...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 14th to review third-quarter results. Joaq...